Leukemia and lymphomatous meningitis remains a unique concern in recurrent hematological malignancies associated with a high risk of central nervous system (CNS) involvement. The incidence of CNS relapses of leukemia after hematopoietic stem cell transplantation (HSCT) ranges from o5% among patients without a history of CNS disease and up to 27% among patients with prior CNS involvement pre-HSCT. There are conflicting studies as to the effectiveness of post-HSCT intrathecal (IT) chemotherapy prophylaxis in preventing CNS recurrence. Some studies have shown significantly higher recurrence rates in patients at risk of CNS relapse, whereas others have been unable to show much of a difference. 1 These results likely reflect differences in patient populations as well as prophylactic strategies. However, there is a paucity of prospective data to truly compare the results of different prophylactic strategies. In addition, agents that have been shown to be effective in the treatment and prevention of leukemia or lymphoma meningeal disease require frequent administration in order to maintain appropriate cytotoxic concentrations. Liposomal cytarabine is a sustained release liposomal formulation of cytarabine approved for IT or intraommaya treatment of recurrent lymphomatous meningitis that allows for sustained release of cytarabine with prolonged therapeutic concentration and thus prolonged drug exposure of up to 8 days in children and 14 days in adults. [2] [3] [4] The use of liposomal cytarabine could potentially overcome some of the barriers to post-HSCT administration of CNS prophylaxis and may provide for improved outcome results. The primary objectives of this single-institution study were to determine the safety and tolerability of liposomal cytarabine as prophylaxis prior to and following HSCT in pediatric recipients with acute leukemia and non-Hodgkin lymphoma at risk of CNS recurrence post HSCT.
All patients aged 2-25 years with a histologically proven diagnosis of acute leukemia (ALL or AML) or non-Hodgkin lymphoma (lymphoblastic lymphoma, Burkitt lymphoma and diffuse large B-cell lymphoma) who underwent either autologous or allogeneic HSCT and considered to be at risk of a CNS relapse either due to known prior history of leptomeningeal disease or risk for future recurrence were eligible to receive liposomal cytarabine prophylaxis prospectively. Risk of CNS recurrence was determined based on the number of relapse and underlying biological risk factors of primary disease. HSCT protocols were approved by the local institutional review board, and all patients signed informed consent. Conditioning regimens were largely protocol driven and disease specific and consisted of both myeloablative conditioning (n = 19, 76%) and reduced toxicity conditioning (n = 5, 24%) selected according to the patient's disease status, organ function and performance status as we have previously described. [5] [6] [7] Fifteen patients received a TBI (1200 cGy)-containing conditioning regimen. Six patients received an additional CNS boost of up to 1200 cGy. Acute GVHD prophylaxis consisted of tacrolimus and mycophenolate mofetil with dosage adjustment to maintain safe and therapeutic blood levels and utilized standard supportive care measures as we have previously described. [8] [9] [10] All patients developing ⩾ Grade II acute GVHD received systemic corticosteroid therapy (minimum equivalent 2 mg/kg of prednisone per day). Commercial supply of liposomal cytarabine (DepoCyt, Sigma-Tau Pharmaceuticals, Inc, Gaithersburg, MD, USA) was utilized from single-use 5-mL vials containing 50 mg (10 mg/mL) each. The appropriate dose (35 mg for children o 21 years or 50 mg ⩾ 21 years) was administered IT either via lumbar puncture or through an intraventricular ommaya reservoir. All patients received concurrent dexamethasone (0.15 mg/kg/dose (maximum 4 mg/dose) PO BID) treatment starting the day of and for 5 days after IT administration of the drug to prevent arachnoiditis as previously described. 2 All patients received at least one dose of liposomal cytarabine either prior to or during HSCT conditioning. Some patients received maintenance therapy, which was then administered a minimum of once post HSCT with subsequent dosing allowed every 3 months post HSCT for up to 1 year. CSF studies, including cell counts, protein, glucose and cytology, were obtained prior to each dose of liposomal cytarabine. Brain magnetic resonance imaging and/or computed tomographic scan for evaluation of CNS disease status were obtained for patients with positive CNS findings or as clinically indicated. Toxicities are reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE 4.0). All patients were assessed for toxicity if they received at least one dose of liposomal cytarabine.
A total of 24 patients (14 ALL, 3 AML, 3 DLBCL, 3 Burkitt and 1 T-cell lymphoblastic lymphoma) was prophylaxed with at least one dose of liposomal cytarabine over an 8-year period from 2004 to 2012. All patients who received IT liposomal cytarabine were assessable for toxicity. The median age was 12 years (range 6-22 years). Twenty-one patients were prophylaxed with the 35-mg dose and 3 patients received the 50-mg dose of liposomal cytarabine. A total of 8 patients (33%) had been CNS positive prior to HSCT and 16 patients (67%) were CNS negative prior to HSCT but were at high risk of CNS recurrence post HSCT. All patients with hematological malignancies were in a CNS and systemic CR at the time of HSCT (6 CR1, 2PR/induction failure, 11 CR2, 5 CR3). Patients who were a PR or primary induction failure as an indication for transplant were able to achieve CR prior to proceeding. All patient characteristics and outcomes are listed in Table 1 .
There were a total of 50 doses administered over an 8-year time period (median per patient = 1; range 1-12 doses). Doses were given at least once prior to HSCT. Patients were given additional dosing as needed prior to HSCT based on CNS disease status following previous published induction dosing regimens.
2 Post-HSCT doses were given at the discretion of the treating physician and varied among patients but typically were given 2-3 months apart. Seventeen patients received 1-2 doses, 4 patients received 3-4 doses, 1 patient received 8 doses, 1 patient received 9 doses and 1 patient received 12 doses. Overall, IT administration of liposomal cytarabine was generally well tolerated in all patients. Toxicities did not differ based on timing of administration pre-or Letter to the Editor post HSCT. Only one patient developed aseptic meningitis despite dexamethasone use, without the characteristic fever, nausea/ vomiting and severe headache typically associated with arachnoiditis. Other related adverse events included: Grades II-III headache was noted in 1 patient each (8%) and Grades II-III vomiting noted in 2 patients (8%). Head CT scan carried out at the time of symptom occurrence was normal. Patients were treated with supportive therapy and had resolution of symptoms. All liposomal cytarabine-related toxicities are detailed in Table 2 .
The mean follow-up for all 24 patients is 747 days (median, 543 days). At this time, 12 patients are alive and 12 deceased. Of those who have died, cause of death was recurrence of systemic hematological malignant disease in seven patients, organ failure in three patients and overwhelming infection in two patients. No patient developed CNS disease. None of the causes of death were shown to be attributable to CNS disease and/or liposomal cytarabine administration.
In this study, we have demonstrated the feasibility of administering IT or intraommaya liposomal cytarabine to children, adolescents and young adults with hematological malignancy at risk for CNS recurrence after HSCT. Here we demonstrate that this approach is well tolerated as CNS prophylaxis in the pre-and post-HSCT recipients. These observations are similar to what has been observed in the adult and pediatric trials not utilizing HSCT that have been previously published. 2, 3 There also does not appear to be an increase in toxicity when combined with intensive HSCT conditioning regimens with or without TBI and cranial irradiation boosting.
Eight patients presented with CNS disease at the time of their hematological relapse. All eight successfully achieved complete CNS remission after IT liposomal cytarabine and chemotherapy. Furthermore, none of the 24 patients developed CNS relapse after liposomal cytarabine prophylaxis. It is possible that the intensity of the HSCT conditioning regimens, combined with some amount of cranial radiation boost in several of these patients, has contributed significantly to the lack of observed CNS relapses post-HSCT. The detection of occult leptomeningeal minimal residual disease is possible utilizing flow cytometric techniques and can be a useful tool in identifying those patients who have higher risk of CNS relapse and may benefit from augmented prophylaxis versus those who will not. 11, 12 Incorporating liposomal cytarabine into post-HSCT CNS prophylaxis has promise in this regard. With increased utilization both pre-and post HSCT, there will be opportunities to evaluate whether liposomal cytarabine may have a role in either reducing or possibly eliminating the need for cranial boosting during the conditioning regimen prior to HSCT. This would have important implications in decreasing the longterm effects of TBI, cranial boosting and frequent IT chemotherapy administration. Cranial irradiation and chemotherapy have been shown to have significant long-term deleterious effects on children such as intellectual deterioration, multiple endocrinopathies, leukoencephalopathy and secondary oncogenesis. [13] [14] [15] In conclusion, these preliminary results suggest that prophylactic IT or intraommaya liposomal cytarabine is safe, tolerable and effective in pediatric autologous and allogeneic HSCT recipients with hematological malignancy at risk for CNS relapse. Larger phase II/III randomized studies with longer follow-up are needed in the future to compare this to other CNS prophylaxis regimens utilized in pediatric HSCT recipients. Letter to the Editor
